Análisis de la acción Perrigo Company PLC (PRGO)PRGOPerrigo Company PLC

Perrigo Company plc is a pure-play self-care company. The Company provides health and wellness solutions. Its segments include Self Care, Specialty Care, and Infant Formula. Self Care comprises Upper Respiratory, Digestive Health, Pain & Sleep and Healthy Lifestyle product categories globally. Specialty Care comprises our Women's Health and Skin Health product categories globally. Infant Formula comprises the Infant Formula product category, which includes nutritional products designed to meet the dietary needs of infants. It provides a store-branded private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill and Mederma. Its Europe portfolio consists primarily of brands, including Compeed, ellaOne, Solpadeine, Jungle Formula, and ACO. Its upper respiratory products include Nasonex 24HR Energy, Mucus DM, All Day Allergy, Nighttime Cold & Flu, and Allergy Relief. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Perrigo Company PLC is currently a hold. The stock is trading at $15.96, which is above the analyst average target price of $15.25, indicating some market optimism. However, the company is facing financial challenges, as evidenced by a significant net income loss of $1.42 billion in Q4 2025 and a declining gross margin of 30.69% in Q2 2026. Additionally, the stock has seen a 4.03% decrease over the past five days, suggesting recent volatility. Investors should be cautious due to the uncertainty surrounding the CEO transition and the potential impacts on future performance.

18 analysts cover PRGO: 6 rate it Buy, 11 Hold and 1 Sell. The average price target is 20.33.